Positive new data suggests that more people facing advanced breast cancer may be able to put off treatment with harsh ...

For the first time, a medicine aimed directly at the HER2 protein improved overall survival after gastric cancer progressed ...

You also can use them along with chemo or other treatments. Herceptin (trastuzumab) is one of these targeted medicines for breast cancer. It works against a protein called HER2 (also sometimes ...

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

In studies, people who used Herceptin with chemotherapy (traditional drugs used to treat cancer) were more likely to have mild side effects compared with people who used Herceptin alone.

Among patients with HR+/HER2+ breast cancer, Herceptin and Perjeta plus endocrine therapy proved to be beneficial without chemotherapy. Treatment with Herceptin (trastuzumab) and Perjeta (pertuzumab) ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

91.6% of people treated with the Perjeta-based regimen were alive at ten years versus 89.8% of those treated with Herceptin, chemotherapy, and placebo (hazard ratio [HR]=0.83, 95% CI: 0.69-1.00, ...

After ten years, the risk of death was reduced by 17% for people treated with Perjeta (pertuzumab), Herceptin (trastuzumab), and chemotherapy (the Perjeta-based regimen) for a year as post-surgery ...